Study guide

Diagnostic Workup, Biopsy, Imaging, and Pathology Basics

OCN Oncology Certified Nurse Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: OCN Exam Orientation and Official Source Control

Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness

2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care

Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures

3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment

Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation

4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards

Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development

5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy

Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation

6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents

Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation

7 Chapter 7: Symptom Management and Supportive Care

Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination

8 Chapter 8: Oncologic Emergencies and Rapid Escalation

Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

9 Chapter 9: Psychosocial Dimensions of Oncology Care

Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals

10 Chapter 10: Mixed OCN Case Labs

New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab

11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness

Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning

Diagnostic Workup, Biopsy, Imaging, and Pathology Basics

Key Takeaways Explain This Topic AI

Cancer diagnosis usually requires tissue or cytology confirmation; imaging and labs define extent, complications, and treatment readiness.

Biopsy planning weighs safest access, adequate tissue for pathology and biomarkers, bleeding risk, anticoagulants, and infection risk.

Pathology reports may include histology, grade, margins, lymphovascular invasion, receptor status, and molecular markers.

Imaging modalities answer different questions; the nurse coordinates preparation, contrast safety screening, and result follow-up.

Tumor markers such as PSA, CA-125, CEA, AFP, and CA 19-9 support monitoring in select cancers but are not stand-alone screening tests.

Last updated: June 2026

  • Diagnostic Workup, Biopsy, Imaging, and Pathology Basics
  • Diagnostic Thinking in Oncology Nursing

The diagnostic workup answers linked questions: Is cancer present? What type? Where did it start? How far has it spread? Which biomarkers guide therapy? Is the patient safe for the planned procedure? The OCN focuses on assessment, education, specimen awareness, coordination, and complication recognition. A critical boundary: the nurse does not tell a patient they have cancer before provider disclosure, but can explain planned tests and reduce delays. The diagnostic phase is also when uncertainty and anxiety peak, so the nurse manages waiting, clarifies the sequence of tests, and screens for distress while results are pending.

Tissue Diagnosis and Biopsy

Most solid cancers require tissue or cytology confirmation . Biopsy choices depend on suspected type, location, the need for intact architecture, tissue volume for biomarker panels, and procedural risk.

  • Biopsy type What it provides Common use
  • Fine-needle aspiration (FNA) Cells only (cytology) Thyroid nodule, palpable node
  • Core needle Tissue core with architecture Breast, prostate, liver
  • Excisional Entire lesion Small node, suspicious lymph node
  • Incisional Part of a large lesion Soft-tissue sarcoma
  • Endoscopic Tissue from a mucosal surface Colorectal, gastric, lung
  • Bone marrow aspiration/biopsy Marrow cells and architecture Leukemia, lymphoma staging

Nursing preparation confirms allergies, anticoagulant and antiplatelet use, bleeding history, pregnancy status, renal function for contrast, infection symptoms, sedation and transportation plans, and a baseline pain and neurologic exam. Teaching covers purpose, positioning, expected sensations, post-procedure activity limits, when results return, and which symptoms to report.

Post-biopsy complications by site: lung biopsy can cause pneumothorax or hemoptysis; liver biopsy, bleeding or referred right-shoulder pain; bone marrow, localized pain or bleeding; lumbar puncture, post-dural-puncture headache. Escalate dyspnea, chest pain, expanding swelling, uncontrolled bleeding, fever, severe pain, syncope, new weakness, or mental-status change.

Imaging Basics

Modality Common oncology use Nursing considerations

Computed tomography (CT) Anatomy, staging, response, complications Iodinated-contrast allergy, renal function (eGFR), hydration, metformin policy per site

Magnetic resonance imaging (MRI) Brain, spine, pelvis, liver, soft tissue Implant/pacemaker screening, claustrophobia, gadolinium and renal caution

PET/CT (positron emission tomography) Metabolic activity, staging, recurrence Fasting, glucose under ~150-200 mg/dL, inflammation causes false positives

  • Ultrasound Thyroid, breast, liver, fluid guidance Procedure prep, biopsy guidance, ascites evaluation
  • Bone scan Osteoblastic bone activity Hydration, delayed imaging, arthritis/fracture false positives
  • Mammography Breast screening and diagnosis Prior images, compression teaching, follow-up coordination

Key safety teaching: PET uses radiolabeled glucose (fluorodeoxyglucose), so elevated blood glucose can blunt tumor uptake; hold metformin per site policy after iodinated contrast because of lactic-acidosis risk if renal function declines; and screen every MRI patient for implanted metal.

Pathology Report Literacy

A pathology report may include specimen site, histologic type , tumor size, grade , margin status , lymphovascular and perineural invasion, lymph-node involvement, receptor status, immunohistochemistry, and molecular findings. A breast report often lists invasive ductal carcinoma, Nottingham grade, ER/PR/HER2, Ki-67 proliferation index, margins, and nodes. A colorectal report often lists adenocarcinoma, depth of invasion, nodes, margins, lymphovascular invasion, and mismatch-repair status.

Histology names the tissue pattern: adenocarcinoma, squamous cell carcinoma, small cell carcinoma, melanoma, sarcoma, lymphoma, leukemia, glioma, or germ cell tumor. Cytology evaluates loose cells without full architecture and may be sufficient (thyroid FNA) or insufficient (when grading and invasion matter). The nurse recognizes when more tissue is needed for biomarkers and helps obtain outside slides or blocks.

Laboratory and Tumor Markers

Common adjuncts: complete blood count, comprehensive metabolic panel, liver and renal function, coagulation studies, lactate dehydrogenase (LDH), and disease-specific markers. Tumor markers support monitoring more than screening:

  • Marker Associated cancer
  • PSA (prostate-specific antigen) Prostate
  • CA-125 Ovarian
  • CEA (carcinoembryonic antigen) Colorectal
  • AFP (alpha-fetoprotein) Hepatocellular, germ cell
  • CA 19-9 Pancreatic
  • Beta-hCG Germ cell, gestational trophoblastic

Markers can rise from benign conditions and are interpreted as trends by the oncology team. The OCN reduces harm by tracking pending pathology, confirming imaging appointments, ensuring contrast instructions are understood, and escalating urgently for airway compromise, cord-compression symptoms, SVC syndrome signs, sepsis, uncontrolled bleeding, or unstable labs.

Contrast Safety and Pre-Procedure Verification

Contrast safety is a frequent OCN test point. Before iodinated CT contrast, verify renal function (estimated glomerular filtration rate), screen for prior contrast reactions, and follow institutional metformin policy because of the rare risk of lactic acidosis if kidney function falls. Before gadolinium MRI contrast, severe renal impairment raises the risk of nephrogenic systemic fibrosis, so renal function is again checked.

For any biopsy, the nurse confirms the patient has held anticoagulants and antiplatelets per orders, verifies platelet count and coagulation studies, confirms consent, performs a timeout, and reviews the post-procedure monitoring plan. After image-guided procedures, the nurse monitors the site, vital signs, and pain, and provides clear instructions on warning signs and whom to call. These verification habits prevent both procedural harm and delays in starting time-sensitive treatment.

A frequent OCN trap is the patient on a direct oral anticoagulant or low-molecular-weight heparin who was not told to hold it; the nurse confirms the hold window and reschedules rather than proceeding with elevated bleeding risk.